Citations

Clear

942 citation(s) found for "Shi, M".

Cyproheptadine displays preclinical activity in myeloma and leukemia
Mao, Xinliang , Liang, Sheng-Ben, Hurren, Rose, Gronda, Marcela, Chow, Sue, Xu, Gang , Zavareh, Reza Beheshti , Jamal, Nazir, Messner, Hans A., Hedley, David W. , Datti, Alessandro , Wrana, Jeffrey L. , Zhu, Yuanxiao, Shi, Chang-Xin, Tiedemann, Rodger E. , Trudel, Suzanne , Stewart, A. Keith , Schimmer, Aaron D. , Liang, Sheng‐Ben , Wang, Xiaoming , Lee, Kyle

Mayo Clinic

Blood | May 24, 2008 | Volume: 112 | Issue: 3 | Pages: 760-769

10.1182/blood-2008-02-142687 | PMID 18502826 Get It

AbstractD-cyclins are regulators of cell division that act in a complex with cyclin-dependent kinases to commit cells to a program of DNA replication. D-cyclins are overexpressed in many tumors, including multiple myeloma and leukemia, and contribute to disease progression and chemoresistance. To better understand the role and impact of D-cyclins in hematologic malignancies, we conducted a high throughput screen for inhibitors of the cyclin D2 promoter and identified the drug cyproheptadine. In myeloma and leukemia cells, cyproheptadine decreased expression of cyclins D1, D2, and D3 and arrested these cells in the G0/G1 phase. After D-cyclin suppression, cyproheptadine induced apoptosis in myeloma and leukemia cell lines and primary patient samples preferentially over normal hematopoietic cells. In mouse models of myeloma and leukemia, cyproheptadine inhibited tumor growth without significant toxicity. Cyproheptadine-induced apoptosis was preceded by activation of the mitochondrial pathway of caspase activation and was independent of the drug's known activity as an H1 histamine and serotonin receptor antagonist. Thus, cyproheptadine represents a lead for a novel therapeutic agent for the treatment of malignancy. Because the drug is well tolerated and already approved in multiple countries for clinical use as an antihistamine and appetite stimulant, it could be moved directly into clinical trials for cancer.
Glomus tumor and glomangioma of the nerve
Scheithauer, Bernd W., Spinner, Robert J. , Dyck, P. James B. , Edelman, Fredric L., Amrami, Kimberly K. , Fu, Yao‐Shi, Rodríguez, Fausto J. , Salem, A.

Mayo Clinic

Journal of Neurosurgery | February 1, 2008 | Volume: 108 | Issue: 2 | Pages: 348-356

10.3171/jns/2008/108/2/0348 | PMID 18240933 Get It

✓ As a rule, normal human nerve does not contain glomus bodies. Nonetheless, rare examples of glomus tumors do arise in peripheral nerves of various sizes. Their pathobiological characteristics are poorly understood, but reported examples have been small and clinically benign. The authors identified in 1 patient each a glomus tumor and a glomangioma involving nerve. Clinical histories as well as imaging and surgical findings were reviewed. All available H & E–stained slides were examined in both cases. Immunohistochemical stains and electron microscopy, as appropriate, were also performed. The lesions were subtotally and completely resected, respectively. An uneventful postoperative recovery was noted in both patients. Glomus tumors and glomangiomas can involve major nerves on rare occasions. They seem to follow a favorable clinical course, and conservative resection can be of benefit.
Identification of an alternative Gαq-dependent chemokine receptor signal transduction pathway in dendritic cells and granulocytes
Shi, Guixiu , Partida‐Sánchez, Santiago , Misra, Ravi , Tighe, Michael , Borchers, Michael T. , Lee, James J. , Simon, Melvin I., Lund, Frances E. , Partida-Sanchez, Santiago

Mayo Clinic

The Journal of Experimental Medicine | October 16, 2007 | Volume: 204 | Issue: 11 | Pages: 2705-2718

10.1084/jem.20071267 | PMID 17938235 Get It

CD38 controls the chemotaxis of leukocytes to some, but not all, chemokines, suggesting that chemokine receptor signaling in leukocytes is more diverse than previously appreciated. To determine the basis for this signaling heterogeneity, we examined the chemokine receptors that signal in a CD38-dependent manner and identified a novel “alternative” chemokine receptor signaling pathway. Similar to the “classical” signaling pathway, the alternative chemokine receptor pathway is activated by Gαi2-containing Gi proteins. However, unlike the classical pathway, the alternative pathway is also dependent on the Gq class of G proteins. We show that Gαq-deficient neutrophils and dendritic cells (DCs) make defective calcium and chemotactic responses upon stimulation with N-formyl methionyl leucyl phenylalanine and CC chemokine ligand (CCL) 3 (neutrophils), or upon stimulation with CCL2, CCL19, CCL21, and CXC chemokine ligand (CXCL) 12 (DCs). In contrast, Gαq-deficient T cell responses to CXCL12 and CCL19 remain intact. Thus, the alternative chemokine receptor pathway controls the migration of only a subset of cells. Regardless, the novel alternative chemokine receptor signaling pathway appears to be critically important for the initiation of inflammatory responses, as Gαq is required for the migration of DCs from the skin to draining lymph nodes after fluorescein isothiocyanate sensitization and the emigration of monocytes from the bone marrow into inflamed skin after contact sensitization.
A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin
Mao, Xinliang , Stewart, A. Keith, Hurren, Rose, Datti, Alessandro , Zhu, Xuegong, Zhu, Yuanxiao, Shi, Chang‐Xin, Tiedemann, Rodger E. , Eberhard, Yanina, Trudel, Suzanne , Gillis, Lisa, Barber, Dwayne L. , Wrana, Jeffery L., Ezzat, Shereen , Schimmer, Aaron D. , Lee, Kyle , Liang, Sheng‐Ben , Corey, Seth Joel

Mayo Clinic

Blood | September 18, 2007 | Volume: 110 | Issue: 12 | Pages: 4047-4054

10.1182/blood-2007-05-088666 | PMID 17875808 Get It

AbstractThe oncogene c-maf is frequently overexpressed in multiple myeloma cell lines and patient samples and contributes to increased cellular proliferation in part by inducing cyclin D2 expression. To identify regulators of c-maf, we developed a chemical screen in NIH3T3 cells stably overexpressing c-maf and the cyclin D2 promoter driving luciferase. From a screen of 2400 off-patent drugs and chemicals, we identified glucocorticoids as c-maf–dependent inhibitors of cyclin D2 transactivation. In multiple myeloma cell lines, glucocorticoids reduced levels of c-maf protein without influencing corresponding mRNA levels. Subsequent studies demonstrated that glucocorticoids increased ubiquitination-dependent degradation of c-maf and up-regulated ubiquitin C mRNA. Moreover, ectopic expression of ubiquitin C recapitulated the effects of glucocorticoids, demonstrating regulation of c-maf protein through the abundance of the ubiquitin substrate. Thus, using a chemical biology approach, we identified a novel mechanism of action of glucocorticoids and a novel mechanism by which levels of c-maf protein are regulated by the abundance of the ubiquitin substrate.
Protein Kinase C-Mediated Modulation of FIH-1 Expression by the Homeodomain Protein CDP/Cut/Cux
Li, Jin‐Ping , Wang, Enfeng , Dutta, Shamit K., Lau, Julie S., Jiang, Shi-Wen, Datta, Kaustubh , Jiang, Shi‐Wen , Mukhopadhyay, Debabrata

Mayo Clinic

Molecular and Cellular Biology | August 7, 2007 | Volume: 27 | Issue: 20 | Pages: 7345-7353

10.1128/mcb.02201-06 | PMID 17682059 Get It

Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells
Dowdy, Sean C. , Zhou, Xuanting , Hou, Xiaonan , Jin, Fan , Podratz, Karl C. , Jiang, Shi-Wen, Jiang, Shujuan , Jiang, Shi‐Wen

Mayo Clinic

Molecular Cancer Therapeutics | November 22, 2006 | Volume: 5 | Issue: 11 | Pages: 2767-2776

10.1158/1535-7163.mct-06-0209 | PMID 17121923 Get It

Abstract The use of histone deacetylase (HDAC) inhibitors has shown promise for a variety of malignancies. In this investigation, we define the activity of this class of inhibitors in combination with traditional cytotoxic chemotherapy in endometrial cancer cells. Significant reductions in growth were observed in Ark2 and KLE endometrial cancer cells following treatment with paclitaxel, doxorubicin, carboplatin, or the HDAC inhibitor trichostatin A (TSA). However, only combined treatment with TSA/paclitaxel caused synergistic inhibition of cell growth. This combination also resulted in significant changes in cell morphology. Using cell cycle analysis, nuclear staining, and Western blot analysis for poly(ADP-ribose) polymerase and caspase-9 degradation products, TSA/paclitaxel showed the most dramatic activation of the apoptotic cascade. These effects were also observed when the HDAC inhibitors HDAC inhibitor-1 or oxamflatin were substituted for TSA. The anticancer properties of paclitaxel are known to result in part from inhibition of microtubule depolymerization, which results in apoptosis. We show that TSA administration also stabilizes microtubules via α-tubulin acetylation. Furthermore, using Western blot and immunohistochemical analysis, treatment with TSA/paclitaxel led to a significant increase in acetylated tubulin and microtubule stabilization. These effects were confirmed in a mouse xenograft model. Moreover, TSA/paclitaxel resulted in a 50% reduction in tumor weight compared with either agent alone. This study provides in vivo evidence of nonhistone protein acetylation as one possible mechanism by which HDAC inhibitors reduce cancer growth. The TSA/paclitaxel combination seems to hold promise for the treatment of serous endometrial carcinoma and other malignancies with limited sensitivity to paclitaxel. [Mol Cancer Ther 2006;5(11):2767–76]
Histone Deacetylase Inhibitors Decrease DNA Methyltransferase-3B Messenger RNA Stability and Down-regulate De novo DNA Methyltransferase Activity in Human Endometrial Cells
Xiong, Yuning, Dowdy, Sean C. , Podratz, Karl C. , Jin, Fan , Attewell, John R., Eberhardt, Norman L., Jiang, Shi-Wen, Jiang, Shi‐Wen

Mayo Clinic

Cancer Research | September 15, 2005 | Volume: 65 | Issue: 7 | Pages: 2684-2689

10.1158/0008-5472.can-04-2843 | PMID 15805266 Get It

Abstract It is well known that the histone deacetylase (HDAC) inhibitor trichostatin A (TSA) acts synergistically with the DNA methyltransferase (DNMT) inhibitor 5-aza-2′-deoxycytidine (ADC) to reactivate DNA methylation-silenced genes. Moreover, in several studies, TSA was capable of inducing DNA demethylation even in the absence of ADC. Here we describe a mechanism by which HDAC inhibitors affect DNA methylation through their regulation on DNMT3B, a methyltransferase responsible for de novo DNA methylation. Using quantitative real-time PCR and Western blot analysis, we show that TSA down-regulates DNMT3B mRNA and protein expression in human endometrial cancer cells. This decrease in DNMT3B mRNA results in a significant reduction in de novo methylation activities. Further experiments indicated that TSA decreases DNMT3B mRNA stability and reduces its half-life from ∼4 to 2.5 hours. We established that protein synthesis is required for posttranscriptional regulation, suggesting the involvement of an RNase and/or key mRNA stabilization factor(s) controlling the DNMT3B mRNA stability. Therefore, TSA may not only modify histone acetylation, but also potentially alter DNA methylation. Since the HDAC inhibitors are frequently used in epigenetic studies and are considered to be promising anticancer drugs, these new findings will have implications in both laboratory and clinical settings.
Relationship of Late Loss in Lumen Diameter to Coronary Restenosis in Sirolimus-Eluting Stents
O’Malley, A. James , Moses, Jeffrey W. , Leon, Martin B. , Holmes, David R. , Teirstein, Paul S., Schofer, Joachim, Breithardt, Günter, Cutlip, Donald E. , Kereiakes, Dean J. , Shi, Chunxue , Firth, Brian G., Donohoe, Dennis, Kuntz, Richard E., Mauri, Laura , Orav, E. John

Mayo Clinic

Circulation | January 18, 2005 | Volume: 111 | Issue: 3 | Pages: 321-327

10.1161/01.cir.0000153356.72810.97 | PMID 15655127 Get It

Background— Observed rates of restenosis after drug-eluting stenting are low (<10%). Identification of a reliable and powerful angiographic end point will be useful in future trials. Methods and Results— Late loss (postprocedural minimum lumen diameter minus 8-month minimum lumen diameter) was measured in the angiographic cohorts of the SIRIUS (n=703) and E-SIRIUS (n=308) trials. Two techniques, the standard normal approximation and an optimized power transformation, were used to predict binary angiographic restenosis rates and compare them with observed restenosis rates. The mean in-stent late loss observed in the SIRIUS trial was 0.17±0.45 mm (sirolimus) versus 1.00±0.70 mm (control). If a normal distribution was assumed, late loss accurately estimated in-stent binary angiographic restenosis for the control arm (predicted 35.4% versus observed 35.4%) but underestimated it in the sirolimus arm (predicted 0.6% versus observed 3.2%). Power transformation improved the reliability of the estimate in the sirolimus arm (predicted 3.2% [CI 1.0% to 6.7%]) with similar improvements in the E-SIRIUS trial (predicted 4.0% [CI 1.2% to 7.0%] versus observed 3.9%). In the sirolimus-eluting stent arm, in-stent late loss correlated better with target-lesion revascularization than in-segment late loss (c-statistic=0.915 versus 0.665). Conclusions— Because distributions of late loss with a low mean are right-skewed, the use of a transformation improves the accuracy of predicting low binary restenosis rates. Late loss is monotonically correlated with the probability of restenosis and yields a more efficient estimate of the restenosis process in the era of lower binary restenosis rates.
Clustering of the B Cell Receptor Is Not Required for the Apoptotic Response
Trujillo, Miguel A., Jiang, Shi-Wen, Tarara, James E., Eberhardt, Norman L., Jiang, Shi‐Wen

Mayo Clinic

DNA and Cell Biology | September 25, 2003 | Volume: 22 | Issue: 8 | Pages: 513-523

10.1089/10445490360708928 | PMID 14565868 Get It

Cooperative Binding of TEF-1 to Repeated GGAATG-Related Consensus Elements with Restricted Spatial Separation and Orientation
Jiang, Shi‐Wen , Desai, Dinakar, Khan, Sohail, Eberhardt, Norman L.

Mayo Clinic

DNA and Cell Biology | July 26, 2002 | Volume: 19 | Issue: 8 | Pages: 507-514

10.1089/10445490050128430 | PMID 10975468 Get It